Live Breaking News & Updates on Ntibody

Stay informed with the latest breaking news from Ntibody on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ntibody and stay connected to the pulse of your community

Research reveals potential target for enfortumab vedotin therapy in urothelial carcinoma

Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-Nürnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin.

Bonn , Nordrhein-westfalen , Germany , Markus-eckstein-uniklinikum-erlangen , Uniklinikum-erlangen , Markus-eckstein , Department-of-urology , University-hospital-bonn , Institute-of-pathology , Hospital-bonn , Assistant-physician , Clinician-scientist

Bivalent COVID-19 vaccine boosts immunity but needs to be updated

A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less abundantly, according to a Brazilian study reported in the Journal of Medical Virology.

Bahia , Brazil , China , Barreiras , United-states , Wuhan , Hubei , Brazilian , Jaime-henrique-amorim , Souza-ferreira , Covishield-oxford-astrazeneca , Milena-silva-souza

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

New research to be presented at next week's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients.

Barcelona , Comunidad-autonoma-de-cataluna , Spain , Amsterdam , Noord-holland , Netherlands , Magda-vergouwe , Global-congress , Escmid-global-congress , University-of-amsterdam , Amsterdam-university-medical-centerin , Centre-for-experimental

Aging affects immune response and virus dynamics in COVID-19 patients, study finds

A study examining 1031 hospitalized COVID-19 patients found that aging significantly impacts immune responses, viral dynamics, and the nasal microbiome, with older adults experiencing more severe disease symptoms and delayed viral clearance.

United-states , Science-translational-medicine , Corona-borealis-studio , Severe-acute-respiratory-syndrome-coronavirus , Phenotyping-assessment , Aging , Ovid-19 , Mmune-response , Irus , Ntibody , Lood

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

United-states , Texas , American , Klus-pharma , Jordi-rodon , Timothy-yap , Merck-co , Development-agreement , Andrew-sabin-family-fellowship-program , American-association-for-cancer-research , University-of-texas-md-anderson-cancer-center , Experimental-therapeutics-clinical-trials-network

Rogue immune cell found to cause poor antibody responses in chronic viral infections

Australian researchers have discovered a previously unknown rogue immune cell that can cause poor antibody responses in chronic viral infections.

Monash , South-australia , Australia , Australian , Lucy-cooper , Monash-university-biomedicine-discovery-institute , Monash-university , Professor-kim-good-jacobson , Kim-good-jacobson , Chronic , Ntibody

Research identifies how leukemia develops resistance to first line treatments

Relapses in a common form of leukemia may be preventable following new research which has identified how the cancer develops resistance to first line treatments.

Melbourne , Victoria , Australia , Terry-rabbitts , Terry-rabbitt , Constanze-bonifer , Institute-of-cancer , Newcastle-university , University-of-birmingham , University-of-virginia , Genomic-sciences , University-of-melbourne

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.

Kateryna-kon , Vaccine-development , Npj-vaccines , Reverse-vaccine-development , Antimicrobial-resistance , Accine , Ntibody , Linical-trial , Oronavirus , Fficacy , Iv , Mmunodeficiency

Mayo Clinic, Terasaki Institute announce research collaboration for improving organ transplant outcomes

Mayo Clinic and Terasaki Institute for Biomedical Innovation announced today a research collaboration centered on improving organ transplant outcomes.

United-states , Minnesota , Florida , Arizona , Pauli-terasaki , Ali-khademhosseini , Burcin-taner , Terasaki-institute-for-biomedical-innovation , Terasaki-institute , Mayo-clinic-transplant-center , Mayo-clinic-transplant-specialty-council , Terasaki-institute-of-biomedical-innovation

Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.

San-diego , California , United-states , American , Rebecca-porter , American-association-for-cancer-research , Dana-farber-cancer-institute , Farber-cancer , Gynecological-oncology-program , American-association , Cancer-research , Annual-meeting